Successful treatment of refractory lupus nephritis by the sequential use of rituximab and belimumab

Joint Bone Spine

Volumn 84, Issue 2, 2017, Pages 235-236

  Simonetta, Federico ^a,b   Allali, Danièle ^a   Roux Lombard, Pascale ^a   Chizzolini, Carlo ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b University Hospital and Faculty of Medicine   (Switzerland)

Author keywords

BAFF; Belimumab; Lupus nephritis; Rituximab; SLE

Indexed keywords

ANTINUCLEAR ANTIBODY; B CELL ACTIVATING FACTOR; BELIMUMAB; COMPLEMENT; CORTICOSTEROID; CREATININE; DOUBLE STRANDED DNA ANTIBODY; HYDROXYCHLOROQUINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MONOCYTE CHEMOTACTIC PROTEIN 1; MYCOPHENOLATE MOFETIL; PREDNISONE; PROTEIN; RITUXIMAB; TUMOR NECROSIS FACTOR; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ALOPECIA; ANTIBODY TITER; ARTHRALGIA; CASE REPORT; CLINICAL FEATURE; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG DOSE SEQUENCE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HEMATURIA; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LETTER; LUPUS ERYTHEMATOSUS NEPHRITIS; PROTEINURIA; RISK BENEFIT ANALYSIS; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; YOUNG ADULT; COMBINATION DRUG THERAPY; DOSE RESPONSE; DRUG ADMINISTRATION; FOLLOW UP; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; RITUXIMAB; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84970006655     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2016.01.008     Document Type: Letter

References (5)

1. [1] Sang, A., Zheng, Y.Y., Morel, L., Contributions of B cells to lupus pathogenesis. Mol Immunol 62 (2014), 329–338.
2. [2] Duxbury, B., Combescure, C., Chizzolini, C., Rituximab in systemic lupus erythematosus: an updated systematic review and meta-analysis. Lupus 22 (2013), 1489–1503.
3. [3] Vincent, F.B., Morand, E.F., Schneider, P., et al. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol 10 (2014), 365–373.
4. [4] Carter, L.M., Isenberg, D.A., Ehrenstein, M.R., Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. Arthritis Rheum 65 (2013), 2672–2679.
5. [5] Kraaij, T., Huizinga, T.W., Rabelink, T.J., et al. Belimumab after rituximab as maintenance therapy in lupus nephritis. Rheumatology (Oxford) 53 (2014), 2122–2124.